2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Study Population, Animal Model
PAPER

2555 Cholesterol biosynthesis is essential to the cytotoxicity observed following autophagy disruption in myeloma

Daniel K.C. Lee, PhD, Cecilia Bonolo De Campos, PhD2, Ding Wang, PhD3, Henrietta W. Bennett, PhD4, Diandra Zipinotti Dos Santos, PhD5, Ruijuan He6, Tessa Pelino7, Ellen Nong Wei8, Dory David Abelman9, Jeffrey Bruce, PhD10, Craig Simpson, PhD11, Leanne Wybeng-Groot, PhD12, Michael F Moran, PhD13, Rodger Tiedemann, MB, PhD14, Trevor Pugh, PhD15, Linda Penn, PhD16, Suzanne Trudel, MD17, Keith Stewart, MD18
1 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
2 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
3 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
4 Advanced Optical Microscopy Facility, University Health Network, Toronto, Canada
5 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
6 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
7 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
8 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
9 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
10 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
11 Program in Cell & Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada
12 Program in Cell & Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada
13 Program in Cell & Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada
14 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
15 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
16 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
17 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
18 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Given the essential role of the lysosome and autophagy in plasma cell homeostasis and antibody production, disrupting this pathway has emerged as a promising therapeutic strategy for multiple myeloma (MM). Previously, our group identified one such lysosomal function and autophagy regulator, PIKfyve, as a therapeutic vulnerability in MM.

To characterize the downstream effects of targeting PIKfyve in MM, we performed unbiased transcriptomics and proteomics on six human myeloma cell lines (HMCLs) following treatment with a novel PIKfyve inhibitor, PIK001. Consistent with known activity, lysosomal- and autophagy-related biological pathways were among the most significantly enriched in treated cells. Surprisingly, however, cholesterol homeostasis was the most significantly enriched pathway following PIKfyve inhibitor treatment. Analysis across the cholesterol biosynthesis pathway revealed a robust induction of key enzymes, including HMGCS1, FDFT1, and IDI1. Consistent with these findings, total cholesterol levels increased by 1.5- to 2-fold in PIKfyve inhibitor-treated HMCLs. Furthermore, treatment resulted in a significant enlargement of LAMP1-positive lysosomes with significant colocalization of the cholesterol-binding dye filipin, indicating cholesterol accumulation.

We next evaluated combining PIK001 with several cholesterol-lowering drugs, including fluvastatin, lycorine, NB-598, and U18666A. Strong antagonism was observed, indicating that cholesterol is absolutely required for the cytotoxic effects of PIKfyve inhibition. Because PIKfyve is a critical regulator of lysosomal function and autophagy, we examined whether cholesterol also modulates these downstream effects. In MM cells, as expected, PIK001 treatment increased the levels of the autophagy markers LAMP1, p62, and LC3A/B, consistent with impaired autophagic flux, whereas co-treatment with fluvastatin reduced their accumulation. Similarly, PIK001 treatment increased lysosomal pH and impaired lysosomal function, as evidenced by defective cathepsin maturation and reduced intracellular lysosomal activity, both of which were restored by fluvastatin co-treatment. These findings demonstrate that lysosomal cholesterol accumulation induced by PIKfyve inhibition substantially contributes to impaired autophagic flux and cell death.

To determine whether these findings extend beyond HMCLs, we next evaluated the effects of PIKfyve inhibition in primary MM patient samples and in vivo models. Primary CD138+ MM cells treated with PIK001 also showed significant upregulation of genes associated with cholesterol homeostasis. Furthermore, synergy analysis of patient-derived CD138+ cells treated with PIK001 and fluvastatin revealed a strong antagonistic interaction, recapitulating the cholesterol-dependent effects observed in HMCLs. In the Vκ*MYC mouse model, mice were randomized to receive vehicle, a PIKfyve inhibitor, fluvastatin, or the combination daily. Monoclonal gammopathy was ablated, and survival was prolonged in PIKfyve inhibitor-treated mice; however, co-treatment with oral fluvastatin abrogated the anti-tumor and survival effects.

Clinically relevant anti-MM therapeutics were then evaluated to define the specificity and broader relevance of this cholesterol response. Bortezomib and dexamethasone had no effect on total cholesterol levels or cholesterol biosynthesis enzyme expression. Interestingly, however, as with PIKfyve inhibition, lenalidomide and iberdomide also increased also total cholesterol levels, albeit to a lesser extent and through what appears to be a distinct mechanism. Finally, in solid tumor cell lines (i.e. pancreatic, prostate, and renal cell carcinoma), as in MM, autophagy disruption also resulted in increased total cholesterol levels and upregulation of cholesterol biosynthesis enzymes (although solid tumors are sensitive only at much higher inhibitor doses), demonstrating that this response to lysosome/autophagy disruption extends beyond myeloma.

In summary, cholesterol accumulation is a critical mediator of PIKfyve inhibition-induced autophagy disruption and subsequent MM cell death. Invoking overproduction of cholesterol within MM (and other blood cancers that are disproportionally sensitive to autophagy disruption) may prove to be an unexpected therapeutic avenue that has not previously been pursued.
Daniel K.C. Lee, PhD: No relevant conflicts of interest to declare.